GLP-1 receptor agonists like semaglutide and tirzepatide produce remarkable metabolic benefits. They also, in a subset of users, trigger anxiety that disrupts sleep onset. This anxiety is not always mild. Some individuals report racing thoughts, hyperarousal, and a sense of unease that delays sleep by hours. When this happens, the metabolic gains of GLP-1 therapy become overshadowed by cognitive fatigue and poor recovery. Clinicians and researchers have begun to explore peptide-based anxiolytics that might counteract this side effect without blunting the therapeutic action of GLP-1 agonists. One candidate that appears repeatedly in the Russian-language literature is Selank (a synthetic heptapeptide analogue of tuftsin).
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its design aimed to combine the immunomodulatory properties of tuftsin with anxiolytic effects mediated through central nervous system mechanisms. Early work by Khavinson and colleagues explored Selank's influence on sleep architecture in animal models subjected to chronic stress. They observed that Selank administration normalized sleep latency and increased total sleep time without the sedation typical of benzodiazepines. This finding is relevant because GLP-1 agonist–induced anxiety often presents as a stress-like state, with elevated cortisol and sympathetic tone. Selank appears to modulate GABAergic transmission indirectly, possibly through changes in neuropeptide expression, rather than acting as a direct GABA-A receptor agonist. This mechanism may explain why it does not produce tolerance or withdrawal upon discontinuation.
The connection between GLP-1 receptor activation and anxiety is not fully understood. One hypothesis involves the gut–brain axis. GLP-1 receptors are expressed in the brainstem, hypothalamus, and limbic structures. Agonism at these sites can alter monoamine signaling. In susceptible individuals, this alteration might shift the balance toward anxiogenic pathways. Selank, by contrast, has been shown to increase brain-derived neurotrophic factor (BDNF) expression and modulate serotonin and dopamine turnover in the frontal cortex and hippocampus (Sollertinskaya 2012). These neurochemical changes could buffer the excitatory effects of GLP-1 agonists, allowing sleep onset to proceed more naturally. Except, and this matters, the interaction between Selank and GLP-1 agonists has not been studied directly in controlled human trials. Most evidence comes from separate lines of research that must be triangulated.
Russian researchers have long investigated Selank's effects on sleep in anxiety disorders. In a study by Zozulya and colleagues (2008), patients with generalized anxiety disorder received Selank intranasally for 14 days. Sleep quality improved significantly, measured by the Pittsburgh Sleep Quality Index, and sleep onset latency decreased by approximately 30 percent. The authors noted that the effect was most pronounced in those with high baseline anxiety. This pattern suggests that Selank's sleep-promoting action is secondary to its anxiolytic effect, rather than being a direct hypnotic. For the GLP-1 user experiencing anxiety-driven insomnia, this mechanism is precisely what is needed. A direct hypnotic might deepen sleep but leave the underlying anxiety untreated, leading to poor sleep architecture and next-day grogginess. Selank, in theory, would reduce the cognitive arousal that prevents sleep, allowing natural sleep processes to take over.
Another line of evidence comes from work on Selank's influence on circadian rhythms. In a model of jet lag, Selank accelerated resynchronization of the sleep–wake cycle and reduced anxiety-like behavior during the adjustment period (Khavinson 2015). This finding is relevant because GLP-1 agonists can shift circadian gene expression in peripheral tissues, and possibly in the suprachiasmatic nucleus. If GLP-1 therapy disrupts circadian alignment, the resulting mismatch could manifest as anxiety and insomnia. Selank's ability to facilitate circadian adaptation might therefore address a root cause of the sleep disturbance. Comparisons between Selank and DSIP (delta sleep-inducing peptide) for circadian repair suggest that Selank is superior when anxiety is the primary driver of rhythm disruption, while DSIP may be more effective for purely chronobiological misalignment.
Western literature on Selank is sparse but growing. A 2020 review in the Journal of Psychopharmacology noted that Selank's anxiolytic profile resembles that of buspirone, a 5-HT1A partial agonist, but with a faster onset and fewer side effects. The review also highlighted Selank's nootropic properties, including improved cognitive function under stress. This dual anxiolytic–nootropic action could be particularly beneficial for GLP-1 users who experience anxiety-related cognitive fog during the day. However, the review cautioned that most human studies have been conducted in Russian populations, and replication in diverse cohorts is needed. Another gap is the lack of pharmacokinetic data in the context of GLP-1 agonist co-administration. GLP-1 agonists slow gastric emptying, which could theoretically affect the absorption of orally administered peptides, though Selank is typically given intranasally, bypassing this concern.
Some researchers have proposed that Selank's mechanism involves the modulation of endogenous opioid peptides and the immune system. Tuftsin, the parent molecule, stimulates phagocytosis and antibody-dependent cellular cytotoxicity. Selank retains some immunomodulatory activity, which might be relevant if GLP-1 agonist–induced anxiety has an inflammatory component. Chronic low-grade inflammation is known to disrupt sleep through cytokine-mediated effects on the central nervous system. By reducing inflammation, Selank could indirectly improve sleep onset. This hypothesis remains speculative, but it aligns with broader theories about the role of neuroinflammation in insomnia. Studies on Selank for shift-work sleep disorder have shown reductions in inflammatory markers alongside improvements in sleep quality, lending some support to this idea.
When considering Selank for GLP-1 agonist–induced insomnia, it is important to distinguish it from other sleep peptides. DSIP, for example, promotes slow-wave sleep directly but does not address anxiety. Epitalon, a tetrapeptide that regulates pineal function, may improve circadian alignment but has weaker anxiolytic effects. Tesamorelin, a growth hormone–releasing hormone analogue, can enhance slow-wave sleep but is primarily used for metabolic purposes. Tesamorelin combined with NAD+ has been explored for sleep-disordered breathing in GLP-1 users, a different sleep problem altogether. Selank's niche is anxiety-driven sleep onset delay, where its mechanism matches the underlying pathology.
Open questions remain. Does Selank's anxiolytic effect diminish over time with continued GLP-1 agonist use? Are there any interactions with the incretin system that could alter glucose metabolism? Could Selank's immunomodulatory effects influence the low-grade inflammation associated with obesity and metabolic syndrome? These questions require dedicated research. In the meantime, the available data suggest that Selank is a promising candidate for a specific, underrecognized problem. Its safety profile appears favorable, with no reports of serious adverse events in the published literature. Long-term safety data for many peptides discussed here is limited. Risk profiles should be interpreted accordingly.